Director/PDMR Shareholding

By

Regulatory News | 15 Jul, 2019

Updated : 18:19

RNS Number : 6039F
GlaxoSmithKline PLC
15 July 2019
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W1053

 

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 11 July 2019 on shares held in the Deferred Annual Bonus Plan Post-Tax.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$40.6287

26.529

 

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2019-07-12

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDELFFKDFFBBD

Last news